---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-030719"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2025-10-08T23:59:59+00:00"
generated_at: "2026-05-17T04:17:44.955215+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CervoMed new Phase 2b data: neflamapimod improves CDR-SB in DLB subgroup, reduces GFAP biomarker

## Summary
- In DLB patients with low AD co-pathology (ptau181<21 pg/mL), neflamapimod showed significant improvement on CDR-SB (p=0.005) in within-subject comparison to placebo.
- Neflamapimod reduced the risk of clinically meaningful progression by 75% vs placebo over 16 weeks (p<0.001).
- Plasma GFAP levels decreased by median -23.1 pg/mL on neflamapimod vs +5.8 on placebo (p=0.016); GFAP change correlated with CDR-SB.
- FDA feedback on Phase 3 trial design expected in Q4 2025.
- Two drug capsule batches were used; only the newer batch (NFMD/B) achieved target plasma concentrations.

## SEC filing metadata
- accession: 0001437749-25-030719
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2025-10-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774925030719/0001437749-25-030719-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774925030719/crvo20251008_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-030719
- JSON: https://secwatch.observer/filing/0001437749-25-030719.json
- Plain text: https://secwatch.observer/filing/0001437749-25-030719.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.